The Seventh CNPV Approval
On May 8, 2026, the FDA announced approval of Bizengri (zenocutuzumab-zbco) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion. The approval was granted to Partner Therapeutics. It is the seventh approval under the Commissioner's National Priority Voucher pilot program.
The trial that supported the approval was small by traditional standards — a single-arm study of 19 patients, with an overall response rate of 36.8% and durations of response ranging from 2.8 to 12.9 months. The drug also carried Breakthrough Therapy and Orphan Drug designations. In 2024, it had received accelerated approval for NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma. The cholangiocarcinoma indication is the third in the same fusion-defined franchise.
For sponsors watching the CNPV pilot, the cumulative data point matters more than any single approval. Seven approvals in roughly twelve months tells you something about the agency's tolerance, the program's review velocity, and the kinds of indications that are getting through.
What the Seven Approvals Have in Common
A pattern emerges when you look at the cumulative set of CNPV approvals. Most are for ultra-rare or rare diseases with no approved standard of care. Several involve fusion- or biomarker-defined patient populations. The trial sizes are uniformly small — single-arm studies, basket designs, and registrational trials with fewer than 100 patients are the norm rather than the exception.
The vouchers also share an evidence package shape. The applicant typically brings:
A clear unmet medical need supported by epidemiology and existing treatment landscape data. A biologic rationale that connects the molecular target to the indication. A single-arm or limited-comparator efficacy package with response rates and duration of response as primary outcomes. A safety profile that is acceptable in the context of the indication's mortality and morbidity. A confirmatory commitment with a defined study and timeline.
That shape is reproducible. Sponsors with assets in similar indications — small populations, biomarker-defined, high unmet need — should be reading the CNPV pilot trajectory as a regulatory pathway worth structuring their development plan around. The label-expansion logic that Bizengri demonstrates (NSCLC + pancreatic + cholangiocarcinoma, all NRG1-defined) is also reproducible.
The June 4 Public Hearing
The FDA scheduled a public hearing for June 4, 2026 to solicit feedback on the CNPV pilot. The hearing will cover eligibility criteria, the voucher selection process, sponsor responsibilities, pre-submission requirements, FDA review procedures, the CNPV review council's role, and program implementation. Written comments are open through June 29.
For sponsors with an interest in the pathway, the hearing is the most meaningful single moment in 2026 to influence how the pilot evolves. The format of the hearing — public testimony plus written comment — favours sponsors who arrive with concrete proposals rather than general endorsements. Three areas in particular are worth shaping:
Pre-submission requirements. The current pilot requires substantial pre-submission engagement. The structure and depth of that engagement is one of the strongest determinants of which sponsors end up using the pilot effectively. Specific proposals about what pre-submission packages should contain, and how feedback should be timed, will land with the review council.
Voucher selection criteria. The pilot's selection process for voucher recipients is the program's gating mechanism. Sponsors with assets that fit the pattern of approvals to date have an interest in seeing the selection criteria stated transparently and applied consistently.
Confirmatory commitments. Several of the CNPV approvals have come with substantial confirmatory study commitments. The structure of those commitments — what they look like, what timeline they operate on, what happens if they slip — is the kind of detail that gets settled in pilot evolution rather than in initial design.
The Leadership Risk
The CNPV pilot is most closely associated with the former FDA Commissioner. With Makary's resignation on May 12, the question of whether the pilot continues in its current form, evolves, or pauses is now an open political question.
The June 4 hearing will proceed as scheduled, almost certainly. The decisions that come out of it may take longer than originally planned. Sponsors that were planning to base their 2026-2027 regulatory strategy on continued CNPV access need to plan for both continuation and modification as live scenarios.
The conservative plan is to treat the pathway as available in 2026 and uncertain in 2027. Active development programs that fit the pilot's pattern can be progressed under CNPV assumptions for the current cycle. Programs that would require CNPV access in 2027 need a parallel plan that assumes the pilot is either modified substantially or wound down.
The Writing Work the Pathway Implies
CNPV approvals lean disproportionately on the quality of the regulatory writing. Small trial sizes mean every patient narrative matters more than usual. Biomarker-defined populations require careful framing of the diagnostic landscape and the molecular rationale. Confirmatory commitments need to be specified in detail upfront. Label-expansion stories — the NSCLC-pancreatic-cholangiocarcinoma sequence Bizengri demonstrates — require narrative architecture that can carry across multiple indications without resetting at each one.
For regulatory writing teams supporting assets in CNPV-eligible territory, three concrete preparations matter:
The pre-submission briefing book carries more weight than in a traditional development program. The confirmatory study design conversation has to start earlier in development and be reflected in pre-submission documents. The label proposal needs to anticipate the multi-indication trajectory rather than being scoped only to the primary indication.
These are not new skills. They are the established skills of regulatory writing teams operating in rare and ultra-rare oncology, applied to a pathway that explicitly rewards them. Sponsors that staff for this depth of writing work will find the CNPV pathway more navigable than sponsors that do not.
The pilot has produced seven approvals in roughly twelve months. The next twelve months will tell us whether that pace continues, accelerates, or compresses. The June 4 hearing is the most important data point on the calendar.